Search review questions

Proportion of women having their first OGTT after giving birth a) Postal reminder to woman and physician b) Postal reminder to woman c) Postal reminder to physician · women with previous gestational diabetes mellitus

Proportion of women having a blood glucose test other than an OGTT after giving birth: fasting blood glucose a) Postal reminder to woman and physician b) Postal reminder to woman c) Postal reminder to physician · women with previous gestational diabetes mellitus

Proportion of women diagnosed with type 2 diabetes or showing impaired glucose tolerance or impaired fasting glucose after giving birth · women with previous gestational diabetes mellitus

Health‐related quality of life · women with previous gestational diabetes mellitus

Diabetes‐associated morbidity · women with previous gestational diabetes mellitus

Costs or other measures of resource use · women with previous gestational diabetes mellitus

All‐cause mortality

Cancer occurrence

Health‐related quality of life

Adverse events

Pressure symptoms/cosmetic complaints

Nodule volume reduction ≥ 50%

Socioeconomic effects

All‐cause mortality · participants with type 2 diabetes mellitus

Cardiovascular mortality · participants with type 2 diabetes mellitus

Non‐fatal myocardial infarction · participants with type 2 diabetes mellitus

Non‐fatal stroke · participants with type 2 diabetes mellitus

Amputation of lower extremity · participants with type 2 diabetes mellitus

End‐stage renal disease · participants with type 2 diabetes mellitus

Hypoglycaemia ‐ Severe hypoglycaemia · participants with type 2 diabetes mellitus

Diabetes and non‐diabetes related morbidity · peri‐ or postmenopausal women with type 1 diabetes mellitus

Death from any cause · peri‐ or postmenopausal women with type 1 diabetes mellitus

Adverse effects [ · peri‐ or postmenopausal women with type 1 diabetes mellitus

Health‐related quality of life · peri‐ or postmenopausal women with type 1 diabetes mellitus

Glycaemic control (fructosamine levels) [ · peri‐ or postmenopausal women with type 1 diabetes mellitus

Economic data · peri‐ or postmenopausal women with type 1 diabetes mellitus

Health‐related quality of life [ · participants with type 2 diabetes mellitus Interventions

Death from any cause [ · participants with type 2 diabetes mellitus Interventions

Depression [ · participants with type 2 diabetes mellitus Interventions

Adverse effects [ · participants with type 2 diabetes mellitus Interventions

HbA1c [%] [ · participants with type 2 diabetes mellitus Interventions

Economic data [ · participants with type 2 diabetes mellitus Interventions

All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

Non‐fatal macrovascular outcomes 1. Composite a. Intervention vs metformin [1a. 6 months to 4 years] b. Intervention vs thiazolidinediones [1b. 52 weeks to 4 years] c. Intervention vs meglitinide [1c. 12 months to 15 months]2. Non‐fatal myocardial... · participants with type 2 diabetes mellitus

Microvascular outcomes · participants with type 2 diabetes mellitus

Adverse events 1. All adverse events 2. Drop‐outs due to adverse events 3. Severe hypoglycaemia a. Intervention vs placebo [1a. 24 weeks] [2a. 24 weeks to 56 weeks] b. Intervention vs metformin [1b. 6 months to 4 years] [2b. 24 weeks to 4 years] [... · participants with type 2 diabetes mellitus

Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus

Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus

All‐cause mortality · participants with type 2 diabetes mellitus

Cardiovascular mortality · participants with type 2 diabetes mellitus

Macrovascular outcomes · participants with type 2 diabetes mellitus

Microvascular outcomes · participants with type 2 diabetes mellitus

Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Interventions vs thiazolidinediones [1. 6 months to 12 months] [2. 24 weeks to 52 weeks] · participants with type 2 diabetes mellitus

Cardiovascular mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

Cancer · participants with type 2 diabetes mellitus

Health‐related quality of life · participants with type 2 diabetes mellitus

Non‐fatal macrovascular outcomes 1. Composite 2. Non‐fatal myocardial infarction Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

Microvascular outcomes · participants with type 2 diabetes mellitus

Cancer Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Intervention vs alpha‐glucosidase inhibitors [30 weeks] · participants with type 2 diabetes mellitus